Evidence supporting the use of: Curcumin
For the health condition: Cirrhosis of the Liver

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Curcumin, the active compound found in turmeric (Curcuma longa), has garnered scientific interest for its potential to support or treat cirrhosis of the liver, a condition characterized by progressive scarring and loss of liver function. Several preclinical studies—primarily in animal models—have demonstrated that curcumin exhibits anti-inflammatory, antioxidant, and antifibrotic properties. These mechanisms are relevant because oxidative stress, chronic inflammation, and fibrosis are central to the pathogenesis of cirrhosis. For example, animal studies have shown that curcumin administration can reduce liver enzyme levels, decrease collagen deposition, and inhibit activation of hepatic stellate cells (key drivers of fibrosis). Additionally, curcumin may modulate signaling pathways (such as TGF-β and NF-κB) implicated in liver injury and scarring.

However, high-quality human studies are limited. A small number of pilot clinical trials and observational studies in patients with chronic liver disease (such as nonalcoholic fatty liver disease or hepatitis) suggest some potential for improvement in liver function tests and markers of inflammation, but evidence specifically in cirrhosis remains preliminary. Furthermore, issues with curcumin’s bioavailability and standardized dosing complicate interpretation. Overall, while there is a plausible scientific rationale and some early evidence, robust clinical validation is lacking, so the evidence rating is moderate to low (2/5). Curcumin is not a replacement for standard medical care but is being researched as a possible adjunctive therapy.

More about curcumin
More about Cirrhosis of the Liver